-->

The FDA has granted approval for the use of vorasidenib in the treatment of Grade 2 astrocytoma or oligodendroglioma in patients having a specific IDH1 or IDH2 mutation

The FDA has granted approval for the use of vorasidenib in the treatment of Grade 2 astrocytoma or oligodendroglioma in patients having a specific IDH1 or IDH2 mutation

The FDA has granted approval for the use of vorasidenib in the treatment of Grade 2 astrocytoma or oligodendroglioma in patients having a specific IDH1 or IDH2 mutation

The FDA has granted approval for the use of vorasidenib in the treatment of Grade 2 astrocytoma or oligodendroglioma in patients having a specific IDH1 or IDH2 mutation

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy